A Yale team has developed an alternative gene-editing technology that they say replaces CRISPR’s “hacksaw” effect with a more precise “scalpel.”
A protein that senses and responds to high cholesterol could serve as a new target for drug development.
The complex and intertwined dual epidemics of poorly treated pain and opioid addiction require a combined, artful approach to secure the best possible results…
Cancer and autoimmune startup Cue Biopharma has ended the year with a potentially lucrative new deal with Merck.
Evelo Biosciences has just forged closer ties with a heavyweight academic partner for its monoclonal microbials R&D, which envisages using bacteria to…
Bay Area drug discovery company Verge Genomics has formed industry and academic alliances in neuro disorders.
The gene silencing pioneer expects to complete the submission by the end of the year, setting it up to win approval in the U.S. in 2018.
The series B equips X4 to move deeper into the clinic on two fronts, with phase 2 and 3 trials in cancers and rare diseases on the horizon.
Scientists at Boston Children’s Hospital are developing a PD-L1-boosting therapy to curb the wayward autoimmune reaction that causes Type 1 diabetes.
Xeltis scored €45 million for its restorative, bioresorbable, polymer-based heart valve replacement technology.
Cardinal Health's $1.2 billion deal to offload its Cardinal Health China unit includes pharma and medical products distribution businesses.